A multi-institutional national study has identified unique molecular features responsible for the development and progression of metastatic breast cancer.
Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have found that measuring activation of immune-system B cells may be better than measuring either T-cell activation or the total number of immune cells in and around a tumor, called tumor-infiltrating lymphocytes (TILs), in predicting whether HER2-positive breast cancer responds to treatment.
Immune B-cells May Aid in Predicting HER2+ Breast Cancer Treatment miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.